November 22nd, 2021
•This protocol describes a standardized evaluation of drug sensitivities to targeted signaling inhibitors in NSCLC patient-derived organoid models.
Related Videos
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
High-sensitivity Detection of Micrometastases Generated by GFP Lentivirus-transduced Organoids Cultured from a Patient-derived Colon Tumor
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
High-Throughput In Vitro Assay using Patient-Derived Tumor Organoids
Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs
Generation and Culturing of High-Grade Serous Ovarian Cancer Patient-Derived Organoids
Establishment and Culture of Patient-Derived Breast Organoids
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Author Spotlight: Developing Multiplexed Kinetic Assays for Organoid-Based Drug Response Analysis
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved